FOXP3 Is an X-Linked Breast Cancer Suppressor Gene and an Important Repressor of the HER-2/ErbB2 Oncogene by Zuo, Tao et al.
FOXP3 is an X-linked breast cancer suppressor gene and an
important repressor of the HER-2/ErbB2 oncogene
Tao Zuo2, Lizhong Wang1, Carl Morrison3, Xing Chang1, Huiming Zhang1, Weiquan Li1,
Yan Liu1, Yin Wang1, Xingluo Liu3, Michael W.Y. Chan2, Jin-Qing Liu3, Richard Love4,
Chang-gong Liu2, Virginia Godfrey5, Rulong Shen3, Tim H-M. Huang2, Tianyu Yang3, Bae
Keun Park6, Cun-Yu Wang6, Pan Zheng1, and Yang Liu1
1 Division of Immunotherapy, Department of Surgery, Comprehensive Cancer Center and
Program of Molecular Mechanisms of Disease, University of Michigan, Ann Arbor, MI 48109
2 Program in Molecular, Cellular, and Developmental Biology and Department of Molecular
Virology, Immunology and Medical Genetics; Ohio State University Medical Center and
Comprehensive Cancer Center, Columbus, OH 43210
3 Department of Pathology; Ohio State University Medical Center and Comprehensive Cancer
Center, Columbus, OH 43210
4 Department of Internal Medicine; Ohio State University Medical Center and Comprehensive
Cancer Center, Columbus, OH 43210
5 Department of Pathology, University of North Carolina, Chapel Hill, NC 27599
6 Laboratory of Molecular Signaling and Apoptosis, Department of Biologic and Materials
Sciences, School of Dentistry, University of Michigan
Abstract
The X-linked Foxp3 is a member of the forkhead/winged helix transcription factor family. Germ-
line mutations cause lethal autoimmune diseases in males. Serendipitously, we observed that
Foxp3sf/+ heterozygous mice developed cancer at a high rate. The majority of the cancers were
mammary carcinomas in which the wild-type Foxp3 allele was inactivated and ErbB2 was over-
expressed. Foxp3 bound and repressed the ErbB2 promoter. Deletion, functionally significant
somatic mutations and down-regulation of the FOXP3 gene were commonly found in human
breast cancer samples and correlated significantly with HER-2 over-expression, regardless of the
status of HER-2 amplification. In toto, the data demonstrate that FOXP3 is an X-linked breast
cancer suppressor gene and an important regulator of the HER-2/ErbB2 oncogene.
Introduction
Identification of BRCA1 and BRCA2 marks a key advance in understanding the genetic
defects responsible for breast cancer (Miki, 1994; Wooster, 1995). Several other genes, such
as TP53, PIK3CA and PTEN, have also been implicated in familial and sporadic cancers
(Samuels et al., 2004; Wooster, 2003). However, the genetic defects for breast cancer has
yet to be fully elucidated. There is an important distinction between autosomal and X-linked
#Correspondence: Drs. Yang Liu (Yangl@umich.edu) and Pan Zheng (panz@umich.edu).
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Cell. Author manuscript; available in PMC 2008 June 29.
Published in final edited form as:













genes, as many genes in the latter category are subject to X-inactivation, making it easier to
fulfill Knudson’s two-hit theory (Knudson, 1971). As such, X-linked tumor suppressor
genes can potentially be more important, as LOH or mutation of a single allele can in effect
functionally silence the gene (Spatz, 2004). However, essentially all tumor suppressor genes
are autosomal (Spatz, 2004), although tantalizing evidence concerning abnormalities in the
X-chromosome, including LOH, skewed inactivation and selective loss, has been reported in
breast cancer samples (Kristiansen et al., 2005; Piao and Malkhosyan, 2002; Richardson et
al., 2006; Roncuzzi et al., 2002).
HER-2/Neu/ErbB2 is one of the first oncogenes to be identified (Schechter et al., 1984) and
has been demonstrated to be expressed in a large proportion of cancer cells (Garcia de
Palazzo et al., 1993). The level of HER-2/NEU is an important prognostic marker (Slamon
et al., 1987). Anti-HER-2/NEU antibody Herceptin has emerged as an important therapeutic
for patients with over-expressed HER-2/NEU on cancer tissues (Slamon et al., 2001). Given
the clinical and therapeutic significance of Her-2/Neu/ErbB2 over-expression, it is important
to identify the molecular mechanisms responsible for the over-expression. A well
established mechanism responsible for HER-2 over-expression in human cancer is gene
amplification (Slamon et al., 1987). However, it is unclear whether gene amplification alone
is sufficient to cause HER-2 over-expression. Moreover, a significant proportion of human
cancers with moderate over-expression of HER-2 do not show gene amplification (Bofin et
al., 2004; Jimenez et al., 2000; Todorovic-Rakovic et al., 2005). It is therefore of great
interest to identify regulators for HER-2 expression in breast cancer. In this context, Xing et
al. (Xing, 2000) reported that DNA-binding protein PEA3 specifically targets a DNA
sequence on the HER-2/neu promoter and down-regulates the promoter activity. It is less
clear, however, whether genetic lesions of PEA3 can cause HER-2 over-expression.
Foxp3 was identified during position cloning of Scurfin, a gene responsible for X-linked
autoimmune diseases in mice and humans (Immune dysregulation, polyendopathy,
enterophathy, X-linked, IPEX) (Bennett, 2001; Brunkow, 2001; Chatila, 2000; Wildin,
2001). Serendipitously, we observed a high rate of spontaneous mammary cancer. Our
systemic analyses reported herein demonstrate that the Foxp3 gene is a mammary tumor
suppressor in mice and humans. Moreover, Foxp3 represses the transcription of the HER-2/
ErbB2 gene via interaction with forkhead DNA binding motifs in the ErbB2 promoter.
Results
Spontaneous and carcinogen-induced mammary cancer in Foxp3sf/+ female mice
The mutant BALB/c mice we used for the initial study carried mutations in two closely
linked X-chromosome genes, Foxp3sf and Otcspf. During the course of the study, a
spontaneous segregation of Otcspf allowed us to obtain a BALB/c Otcspf/+ strain.
Meanwhile, we obtained an independent line of Scurfy mice that had never been crossed to
the Spf mutant mice and we backcrossed the Scurfy mutant allele (Foxp3sf) for more than 12
generations into the BALB/c background (Chang et al., 2005). Female mice with only one
copy of the Foxp3 gene survived to adulthood and appeared normal within the first year of
life (Godfrey et al., 1991) with normal T cell function (Fontenot et al., 2003; Fontenot et al.,
2005; Godfrey et al., 1994). Our extended observations of the retired breeders for up to two
years revealed that close to 90% of the Foxp3sf/+Otcspf/+ and Foxp3sf/+ mice spontaneously
developed malignant tumors. Cancer incidences in the littermate controls and a line of
congenic mice with a mutation in Otc but not Foxp3 were comparable with each other (Fig
1A, B). About 60% of the tumors were mammary carcinomas (Fig. 1A, C), although other
tumors, such as lymphoma, hepatoma, and sarcoma were observed. Histological analyses
revealed lung metastasis (Fig. 1A lower panels, based on expression of ER and/or PR, data
not shown) in about 40% of the mice with mammary cancer. More than a third of the tumor-
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bearing mice had multiple lesions in the mammary glands. Most, although not all, mammary
carcinomas expressed the estrogen receptor (ER+, 14/18) and progesterone receptor (PR+,
12/18).
In order to focus on mammary cancer, we treated the mice with a carcinogen, 7,12-
dimethylbenz [a] anthracene (DMBA), in conjunction with progesterone. Mice heterozygous
for Foxp3sf, but not those heterozygous for Otcspf, showed substantially increased
susceptibility to mammary cancer, as revealed by earlier onset, increased incidence (Fig.
1D) and multiplicity (data not shown) of the breast tumors. These data demonstrate that a
mutation of Foxp3, but not Otc results in a major increase in susceptibility to mammary
carcinoma.
Foxp3 expression in normal and cancerous mammary tissues
Since expression of Foxp3 has not been reported in mammary tissue, we isolated normal and
cancerous cells by laser-capture microdissection (Supplemental Fig. S1A) and compared
expression of Foxp3 and Otc by real-time RT-PCR and histochemistry. The complete
absence of the cd3 transcripts (Fig. S1B) indicated that the micro-dissected samples were
devoid of T cells, the main cell types known to express Foxp3 (Fontenot et al., 2005). A
representative profile and summarized data of Foxp3 expression in Foxp3sf/+Otcspf/+ mice
and age-matched WT control mice are shown in Fig. 2A. Foxp3 mRNA was detected in
normal mammary epithelium from both the WT and Foxp3sf/+Otcspf/+ mice, but not in
mammary cancer cells from the same Foxp3sf/+Otcspf/+ mice. Immunohistochemical
staining (Fig. 2B) confirmed the loss of expression of Foxp3 in the mammary carcinoma
generated from the Foxp3sf/+Otcspf/+ mice.
Foxp3 is an X-linked gene that is subject to X-chromosomal inactivation (Fontenot et al.,
2005). We carried out an anchored RT-PCR and cloned the low levels of Foxp3 mRNA in
the breast tissues. We sequenced the cDNA clones from pooled samples after ruling out
potential T cell contamination (based on a lack of T-cell specific cd3 transcripts, Fig. S1B).
As shown in Fig. 2C, 100% of the Foxp3 transcripts in the cancerous tissues were from the
mutant alleles, which indicate that the wild-type allele was silenced in the tumor cells. In
contrast, the transcripts from the mutant allele constituted 15% of the transcripts in the
normal mammary samples from the same mice. Thus, the expression pattern of Foxp3
fulfills another criterion for a tumor suppressor gene.
FOXP3 is a repressor of ErbB2 transcription
Our characterization of the mammary tumors in the mutant mice revealed wide-spread up-
regulation of ErbB2, in contrast to those rare tumors from WT mice, as shown in Figure 3A
and supplemental Table S1. Using real-time RT-PCR, 8–12-fold more ErbB2 mRNA was
found in the cancer cells than in normal epithelium (Fig. 3A). There was also more ErbB2
mRNA in the Foxp3sf/+spf/+ epithelium than in that of the WT female mice (Fig. 3A), which
indicates a potential gene dosage effect of Foxp3 on the regulation of ErbB2 expression in
vivo. Transfection of the TSA cell line with Foxp3 cDNA repressed ErbB2 levels on the
TSA cell line (Fig. 3B).
Analysis of the 5′ sequence of the ErbB2 gene revealed multiple binding motifs for the
forkhead domain (Fig. 3C). To test whether Foxp3 interacts with the ErbB2 promoter, we
used anti-V5 antibody to precipitate sonicated chromatin from the TSA cells transfected
with the Foxp3-V5 cDNA and used real-time PCR to quantitate the amounts of the specific
ErbB2 promoter region precipitated by the anti-V5 antibodies in comparison to those that
bound to mouse IgG control. As shown in Fig. 3C, the anti-V5 antibodies pulled down
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significantly higher amounts of ErbB2 promoter DNA than the IgG control, with the highest
signal around 1.6 kb 5′ of the transcription starting site.
To test whether the binding correlated with the suppression by Foxp3, we produced
luciferase reporter using the 1.8, 1.2 and 0.8 Kb upstream of the ErbB2 TSS and tested the
ability of Foxp3 to repress ErbB2 promoter activity. In three separate cell lines, we observed
that the region with the strongest ChIP signal was required for optimal repression by Foxp3
(Fig. 3D). Furthermore, we deleted two potential Foxp3-binding sites based on intensity of
ChIP signal, abundance of consensus binding sites and conservation between mouse and
human (Supplemental Fig. S2) by site-directed mutagenesis and measured the effect on
Foxp3-mediated repression. As shown in Fig. 3E, deletion of either binding site substantially
increased the ErbB2 promoter activity in the presence of Foxp3 and thus alleviated Foxp3-
mediated repression.
Since the region deleted in mut B is 100% conserved between mouse and man and since this
deletion completely wiped out repression, we used an electrophoretic mobility shift assay
(EMSA) to determine whether the forkhead DNA-binding motifs in region B bound to
Foxp3. As shown in Fig. 3F, the nuclear extracts from the Foxp3-expressing cells
specifically retarded migration of the WT but not mutant 32P-labeled probes compared with
control cells. While mutant cold probes did not affect Foxp3 binding activities, WT cold
probes significantly diminished them, establishing that the binding of these complexes is
specific to forkhead DNA-binding motifs. We therefore carried out site-directed
mutagenesis to replace the 12 nucleotides (mut C) within the ErbB2 promoter and compared
the promoter activity and Foxp3-repression by luciferase assays. While the wild-type
promoter was repressed by Foxp3, no repression by Foxp3 was observed when the mutant
promoter was used. Moreover, in contrast to the deletional Mut B, the mutations had no
impact on the basal activity of the ErbB2 promoter (Fig. 3G). Taken together, our new data
make a compelling case that Foxp3 represses the ErbB2 promoter via specific forkhead
binding motifs.
FOXP3 defects in human breast cancer
We analyzed the levels and isoforms of the FOXP3 transcripts in a panel of normal human
mammary epithelial cells (HMEC), an immortalized but non-malignant cell line
(MCF-10A), and 10 malignant breast cancer cell lines differing in ER/PR and HER-2 status.
Early passage of HMEC with no methylation in the CpG island of the P16 promoter
(supplemental Fig. S3) was used to avoid effects associated with P16 inactivation in post-
senescence HMEC cultures (Romanov et al., 2001). As shown in Fig. 4A, similar levels of
FOXP3 transcripts were observed in two independent isolates of HMEC and in the
immortalized cell line MCF-10A. Each of the 10 tumor cell lines had a different degree of
reduction in FOXP3 mRNA levels in comparison to HMEC and MCF-10A. Among them, 2
were completely devoid of FOXP3 mRNA, while the others had a 1.5–20 fold reduction. We
then used anchored primers spanning exons 1–12 to amplify the FOXP3 transcripts, and
then we sequenced the PCR products. As shown in Fig. 4, none of the tumor cell lines
expressed full-length FOXP3 transcripts. The HMEC expressed the same two isoforms as
observed in the T cells, while MCF-10A expressed the exon 3-lacking. The same isoform
was also found in 4 tumor cell lines at much lower levels. In addition, 3 tumor cell lines
expressed an isoform lacking both exons 3 and 4. The alternative splicing resulted in a
frame-shift beginning at codon 70 and an early termination at codon 172. Furthermore, 2
tumor cell lines expressed a FOXP3 isoform lacking exons 3 and/or 8. Exon 8 encodes the
leucine-zipper domain that is frequently mutated in IPEX patients (Ziegler, 2006). Thus,
FOXP3 is abnormal in breast cancer cell lines. Consistent with a role for FOXP3 in
repressing HER-2 expression, the majority of the breast cancer cell lines had higher levels of
HER-2 in comparison to normal HMEC (Fig. 4, lower panel). However, additional changes
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are also likely required for HER-2 over-expression, as three cell lines did not over express
HER-2 even though the FOXP3 transcripts were greatly reduced.
We took three approaches to determine whether the findings in the mutant mice and human
breast cancer cell lines are relevant to the pathogenesis of human breast cancer. First, we
used immunohistochemistry to determine expression of FOXP3 in normal vs. cancerous
tissue. As shown in Fig. 5A, while more than 80% of the normal breast samples expressed
FOXP3 in the nuclei of the epithelial cells, less than 20% of the cancerous tissue showed
nuclear staining. Second, we used fluorescence in situ hybridization (FISH) to determine
whether the FOXP3 gene was deleted in the breast cancer samples. The minimal common
region of deletion was identified using flanking p-telomeric and centromeric clones. Out of
223 informative samples, we observed 28 cases (12.6%) with deletions in any of the three
loci. Interestingly, deletion of the FOXP3 locus was found in all of the 28 cases (Fig. 5B and
supplemental Table S2). These data suggest that FOXP3 is likely within the minimal region
of deletion in the Xp11 region studied. Although all deletions were heterozygous, the
FOXP3 protein was undetectable in 26/28 cases. Thus, it appears that for the majority of the
breast cancer samples, LOH alone was sufficient to inactivate the locus, perhaps due to X-
chromosomal inactivation. The two cases with both deletion and FOXP3 expression had X-
polysomy with 3 and 4 X-chromosomes respectively (Table S2). Thirdly, we isolated DNA
from matched normal and cancerous tissues (50 cases with formalin fixed samples and 15
cases of frozen samples) from patients with invasive ductal carcinoma and amplified all 11
coding exons and intron-exon boundary regions by PCR. Two independent PCR products
were sequenced in order to confirm the mutations. Unless the bulk sequencing data were
unambiguous (Supplemental Fig S4a & c), the PCR products were cloned and 5–10
independent clones from each reaction were sequenced (Supplemental Fig. S4b). Among the
formalin fixed samples, we only used the cases in which the normal tissue samples gave
unambiguous sequencing data that matched the wild-type FOXP3 sequence. When the
cancerous tissues were compared with normal tissues from the same patient, 36% (18/50
formalin-fixed samples and 5/15 frozen samples) showed somatic mutations (Table S3).
Loss of the wild-type allele was found in 6/23 cases (38%) of cancer samples with somatic
FOXP3 mutations (See supplemental Fig. 4c for an example). The other cases had
heterozygous mutations (Supplemental Fig. S4a). Eighteen mutations resulted in the
replacement of amino acids. Most are likely to be critical for FOXP3 function, as judged
from the pattern of mutation in IPEX patients (Ziegler, 2006) or in the conserved zinc finger
domain that has so far not been implicated (Fig. 5C).
Although most samples had a single mutation of the FOXP3 gene, we did observe two cases
with multiple mutations. In the first sample (supplemental Fig S4b, case 3 in Table S3), the
two mutations occurred in consecutive codons, resulting in two nonconservative
replacements of amino acid residues. Clonal analysis revealed that both mutations occurred
in the same clone (Fig. S4b). In the second sample (Table S3, case 16), three mutations
occurred in intron 11. Since this case lacked a WT allele (Supplemental Fig. S4d), it is likely
that all of the mutations occurred in the same allele. The possibility of a mismatch in the
cancer and normal samples was ruled out by comparing the normal and cancer samples for
polymorphism of two unrelated genes (data not shown).
To directly test whether FOXP3 mutations affect the repressor activity for the HER-2 gene,
we chose two representative somatic FOXP3 mutants isolated in the cancer cells and tested
their repressor activity for the HER-2 promoter. One mutation (338P>L) resided in the
signature forkhead domain which is often mutated in the IPEX patient, while the other
double mutation (204C>R205E>K) was from the zinc finger domain that has not been
implicated in IPEX patients. As shown in Fig. 5E, both mutations significantly reduced the
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repressor activity of FOXP3. The reduced repression of the HER-2 promoter correlates with
a significantly reduced inhibition of HER-2 mRNA (Fig. 5D).
Four cases had mutations in introns that may potentially affect RNA splicing. We used laser-
guided micro-dissection to isolate normal and cancerous epithelial cells from one case with a
mutation in intron 6 (case 23, Supplemental Table S3). RNA was isolated and tested for the
potential effects of the mutation on RNA splicing (using primers on exons 5 and 8) and total
FOXP3 transcript, as quantitated by real time PCR using primers spanning exons 10–12.
Tissues from another patient with a mutation in exon 7 were used as control. As show in Fig.
5E left panel, primers spanning exons 5 and 8 failed to detect FOXP3 mRNA from the
cancerous tissue of case No. 23. Furthermore, primers spanning exons 10–12 also failed to
detect any FOXP3 transcripts. Substantial levels were detected in the normal epithelial cells
of the same patients as well as in normal and cancerous tissues from case No. 22. Since the
wild-type allele had been lost in the cancer cells of case No. 23, it is likely that the mutation
in intron 6 inactivated FOXP3. With an intron of 944 nucleotides, a mutation that prevented
splicing of intron 6 would cause premature-termination codon-mediated RNA decay, which
is operative in the FOXP3 gene (Chatila et al., 2000).
FOXP3 defects and HER-2 over-expression
To demonstrate a role for FOXP3 defect in HER-2 overexpression, we first silenced the
FOXP3 gene in early passage of primary HMEC (Supplemental Fig. S3) using a lentiviral
vector expressing FOXP3 siRNA. As shown in Fig. 6A, the FOXP3 siRNA reduced FOXP3
expression by more than 100-fold while increasing HER-2 mRNA by 7-fold. A
corresponding increase in cell surface HER-2 was also observed (Fig. 6B). These results
implicate FOXP3 as a repressor of HER-2 in human breast epithelial cells.
Second, since a major mechanism for HER-2 up-regulation in breast cancer is gene
amplification (Kallioniemi et al., 1992), an intriguing issue is whether FOXP3 is capable of
repressing HER-2 in cancer cells with an amplified HER-2 gene. We produced a Tet-off line
of BT474, a breast cancer cell line known to have HER-2 gene amplification (Kallioniemi et
al., 1992), and transiently transfected it with a pBI-EGFP-FOXP3- vector. After drug
selection, the cells were cultured either in the presence or absence of doxycycline. While the
cells cultured with doxycycline did not express FOXP3 (data not shown), removal of
doxycycline resulted in induction of FOXP3 in a significant fraction of the cancer cells,
which allowed us to compare HER-2 levels in the FOXP3+ and FOXP3− cells in the same
culture by flow cytometry. As shown in Fig. 6C, FOXP3−cells had about a 5–10-fold higher
level of the HER-2 protein on the cell surface in comparison to the FOXP3+ cells.
Thirdly, we compared the expression of FOXP3 with HER-2 expression in breast cancer
tissues. As shown in Fig. 6D, down-regulation of FOXP3 was strongly associated with the
over-expression of HER-2, which supports a role for FOXP3 inactivation in HER-2 over-
expression in breast cancer. Nevertheless, since many of the FOXP3− cells remained
HER-2−, it is likely that dis-regulation of FOXP3 is insufficient for HER-2 up-regulation.
On the other hand, since only 3/82 FOXP3+ cancer cells expressed high levels of HER-2,
FOXP3 inactivation is likely important for HER-2 up-regulation under most circumstances.
Fourth, we divided breast cancer samples based on their HER-2 gene copy numbers and
compared the FOXP3+ and FOXP3− cancer samples for the relative amounts of cell surface
HER-2 expression. As shown in Fig. 6E, in each of the gene dose categories, FOXP3+
samples had reduced HER-2 scores in comparison to the FOXP3− samples. These results
strongly suggest a critical role for FOXP3 in repressing HER-2 expression even in the cases
of HER-2 gene amplification.
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Fifth, of the 223 informative samples among the 238 that we screened for Xp11.2 deletions,
those with deletions encompassing the FOXP3 locus had significantly higher HER-2 scores
compared to those without deletions (P=0.03) (Supplemental Table S4). Likewise, we
compared the relative HER-2 scores among the 50 samples in which we had sequenced all
FOXP3 exons. As shown in Supplemental Table S5, the mutations in the FOXP3 gene
correlated with higher levels of HER-2 (P=0.0083).
Foxp3/FOXP3 inhibits tumorigenicity of breast cancer cells
To test whether the Foxp3 gene can suppress the growth of breast cancer cells, we
transfected the empty vector or the vectors carrying either Foxp3 (mouse or human origin)
or Otc cDNA into three breast cancer cell lines, including mouse mammary tumor cell line
TSA or human breast cancer cell lines MCF7 (ER+HER-2low, no HER-2 amplification) and
SKBr3 (ER-HER-2high with HER-2 amplification). The untransfected cells were removed by
a selection with G418. While the vector-transfected cells grew rapidly, the Foxp3-
transfected cell lines seldom grew into large colonies. The Foxp3-transfected culture had a
drastic reduction in both the size and the number of the drug-resistant colonies. No effect
was observed when the Otc cDNA was used (Fig. 7A&B).
To test whether the somatic mutations uncovered from cancerous tissues ablated their
growth inhibition, we transfected WT and two mutant Foxp3 cDNA into SKBr3 and MCF7
cell lines. As shown in Fig. 7C, in both cell lines, the mutants had a greatly reduced ability
to suppress tumor growth.
To test whether repression of ErbB2 explains the tumor suppressor activity of the Foxp3
gene in the ErbB2+ cancer cell line, we transfected TSA cells with mouse CMV promoter-
driven ErbB2 cDNA cloned into the pcDNA6 vector and evaluated their susceptibility to
Foxp3-mediated growth suppression. In this setting, the expression of ErbB2 was resistant to
Foxp3-mediated repression (data not shown). If repression of endogenous ErbB2 is critical
for Foxp3-mediated tumor suppression, ectopic expression of ErbB2 should alleviate the
growth inhibition by Foxp3. As shown in Fig. 7D & E, while the pcDNA6-vector-
transfected TSA cells remained susceptible to Foxp3-mediated repression, the ErbB2-
transfected TSA cells were completely resistant. In contrast, transfection of c-Myc barely
alleviated the growth inhibition by FOXP3 (Fig. 7E). These results suggest that Foxp3
suppresses TSA growth by repressing transcription of ErbB2.
We transfected TSA cells with either empty vector or V5-tagged Foxp3 cDNA. The stable
transfectant cell lines were selected by G-418. The vector and Foxp3-V5-transfected cell
lines were injected into syngeneic BALB/c mice, which were then observed for tumor
growth and mouse survival. As shown in Fig. 7F, Foxp3-transfectants showed reduced
growth in vivo. The mice that received TSA-vector cells became moribund earlier with
higher incidence, while about 50% of the mice that received the Foxp3-V5-transfected cells
survived more than 7 weeks (Fig. 7G). Similarly, Foxp3-transfected 4T1, a mouse mammary
cancer cell line with ErbB2 over-expression, also showed reduced tumorigenicity in vivo
(data not shown).
Discussion
Foxp3 is an X-linked mammary tumor suppressor gene
Serendipitously, we observed that mice heterozygous for the Foxp3 mutation spontaneously
developed mammary cancer at a high rate. Since two independently maintained lines sharing
the Foxp3 mutation have a comparably higher incidence of mammary cancer, the Foxp3
mutation is likely responsible for the increased rate of breast cancer. Unlike essentially all
cancer suppressor genes identified to date, Foxp3 is X-linked and inactive in cells in which
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the WT allele was silenced by X-inactivation. This is indeed the case as the low levels of
Foxp3 transcripts in the cancer cells were derived exclusively from the mutant alleles.
Our analysis of human breast cancer samples provides strong support for an important role
for the FOXP3 gene in the development of breast cancer. First, we searched X chromosomal
deletion using three markers encompassing more than 10MB of Xp11 and found that
FOXP3 is likely the minimal region of deletion. Second, we revealed a high proportion of
somatic mutations in the FOXP3 gene (23/65 cases over about 2,000 bp exon and intron
sequence scanned). The significance of our finding can be discerned indirectly based on the
fact that the mutations tended to cluster around important domains, such as the FKH and the
zinc finger domains. In addition, most of the mutations resulted in the nonconservative
replacement of amino acids, and cancers with mutations identified had higher levels of
HER-2 than those without mutations. The rate of missense to synonymous mutation was
18/3, which greatly exceeds what would be predicted if the mutations were not relevant to
tumor development. More importantly, we demonstrated that two tested mutations in the
FKH and zing finger domains inactivated the repressor activity and tumor growth inhibition,
and that cancer tissues bearing an intronic mutation had an inactive FOXP3 locus.
Moreover, mutations and deletions of the FOXP3 locus corresponded to increased HER-2
levels. Third, we have documented extensive down-regulation of FOXP3 among more than
600 cases of breast cancer tissues.
Foxp3 is a major transcriptional repressor for ErbB2
The molecular lesions leading to HER-2 over-expression remain poorly understood. Here
we showed that the Foxp3 mutation resulted in over-expression of ErbB2, the murine
homologue of HER-2. In addition, transfection of Foxp3 repressed ErbB2 transcription.
More importantly, chromatin immunoprecipitation and EMSA analyses revealed that Foxp3
binds specifically to its consensus sequence in the 5′ of the ErbB2 gene. Since specific
mutations in the promoter abrogate its susceptibility to repression by Foxp3, such binding is
likely responsible for it.
Importantly, we have demonstrated that, for TSA cell line which has ErbB2 over-expression,
repressing the ErbB2 locus is responsible for Foxp3′s tumor suppressor activity. The
requirement for continuous expression of ErbB2 is best explained by the concept of
oncogene addiction (Weinstein, 2002). However, FOXP3 can also suppress the growth of
tumor cell lines that do not grossly over-express HER-2/ErbB2, such as MCF-7. In an effort
to identify other potential FOXP3 targets, we have produced a FOXP3-Tet-off MCF-7 cell
line that expresses FOXP3 upon removal of tetracycline (Fig. S5a). Using the most current
version of Entrez Gene-based CDFs for a more accurate GeneChip analysis (Dai et al.,
2005), we uncovered wide-spread changes in the expression of genes that are involved in
several pathways critical for cancer cell growth (Fig. S5b). Interestingly, 10 genes involved
in ErbB2 signaling pathway were repressed by FOXP3 (Fig. S5c). Thus, multiple oncogenes
can potentially be up-regulated by FOXP3 inactivation. Taken together, we have
demonstrated that FOXP3 is the first X-linked breast cancer suppressor that represses the
HER-2/ErbB2 oncogene. Given the significant role of HER-2 in the pathogenesis of human
breast cancer and the wide-spread defects of the FOXP3 locus, it is likely that FOXP3 is an
important suppressor for human breast cancer.
Experimental Procedures
Quantitative real-time PCR—Relative quantities of mRNA expression were analyzed
using real-time PCR (Applied Biosystems ABI Prism 7700 Sequence Detection System,
Applied Biosystems). The SYBR (Qiagen) green fluorescence dye was used in this study.
The primer sequences (5′–3′) are listed in Table S6.
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Chromatin immunoprecipitation was carried out according to published procedure (Im et
al., 2004). Briefly, the Foxp3-V5-transfected TSA cells were sonicated and fixed with 1%
paraformaldehyde. The anti-V5 antibodies or control mouse IgG were used to pull down
chromatin associated with Foxp3-V5. The amounts of the specific DNA fragment were
quantitated by real-time PCR and normalized against the genomic DNA preparation from
the same cells.
FOXP3-silencing lentiviral vector—The lentivirus-based siRNA expressing vectors
were created by introducing the murine U6 RNA polymerase III promoter and a murine
phosphoglycerate kinase promoter (pGK)-driven EGFP expression cassette into a vector of
pLenti6/V5-D-TOPO back bone without CMV promoter. A hairpin siRNA sequence of
FOXP3 (target sequence at the region of 1256 to 1274 nucleotides; 5′-
GCAGCGGACACTCAATGAG-3′) was cloned into the lentiviral siRNA expressing vectors
by restriction sites of ApaI and EcoRI.
Immunohistochemistry and Fluorescence In-situ Hybridization (FISH)—HER-2
expression was performed using PathwayTM HER-2 (Clone CB11) (Ventana Medical
Systems, Inc., Tucson, AZ) on the BenchMark® XT automated system per the
manufacturer’s recommended protocol. The HER-2 levels were scored by commonly used
criteria (Yaziji et al., 2004).
FISH for FOXP3 deletion was done using BAC clone RP11-344O14 (ntLocus X:
48,817,975- 48,968,223), which was verified by PCR to contain the FOXP3 gene. The
minimal common region of deletion was done using flanking p-telomeric and centromeric
clones, RP11-573N21 (ntLocus X: 43,910,391-44,078,600) and RP11-353K22 (ntLocus X:
54,416,890- 54,545,788), respectively.
EMSA—Nuclear extracts were prepared as described previously (Wang et al., 1999). The
sequence for the WT probe (W) was AGTTCAATTTGAATTTCAGATAAACG. Mutant
probe (M) (AGTTCAGCGCGAGCGCCAGAGCGCCG) with mutations of all three
potential forkhead binding sites was used as specificity control.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Increased susceptibility to breast cancer in mice heterozygous for Foxp3sf. A. Representative
breast cancers developed in female Foxp3sf/+Otcspf/+ mice. The top panel shows the gross
anatomy while the lower panel shows the histology of local and metastatic lesions of a
breast cancer. B. Cancer-free survival analysis of Foxp3sf/+, Foxp3sf/+Otcspf/+, Otcspf/+ and
WT littermates. Mice were sacrificed when moribund to identify the tissue origins of
cancers. Foxp3sf/+ vs. WT, P<0.0001; Foxp3sf/+ vs. Otcspf/+ , P=0.0003; Foxp3sf/+ vs.
Foxp3sf/+Otcspf/+ , P=0 .9526; Foxp3sf/+Otcspf/+ vs. WT, P=0.0001; Foxp3sf/+Otcspf/+ vs.
Otcspf/+, P=0.0001; Otcspf/+ vs. WT, P=0.4164. C. As in B, except that only incidences of
mammary tumors were included. Foxp3sf/+ vs. Wt: P=0.00015, Foxp3sf/+Otcspf/+ vs. WT:
P=0.00011. D. Increased susceptibility of Foxp3sf/+ mice to carcinogen DMBA and
progesterone. The diagram on top depicts experimental protocol, while survival analysis is
shown in the bottom panel. Foxp3sf/+ vs. WT, P<0.0001; Foxp3sf/+Otcspf/+ vs. Otcspf/+,
P=0.0005; Otcspf/+ vs. WT, P=0.8157. In B & C, those mice that were observed for only part
of the duration were incorporated as censored samples and were marked with a cross in the
Kaplan-Meier survival curves. P values in B&C were derived from log-rank tests.
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Inactivation of the WT Foxp3 allele in mammary cancer cells. A. Defective Foxp3
expression in breast cancer. RNA extracted from the cells isolated by LCM was subjected to
quantitative real-time RT-PCR using primers specific for Foxp3, Hprt and CK19. In the left
panel, fluorescence intensity (ΔRn) was plotted versus cycle number. Mean and S.D. from
three individual mice per group are presented in the right panel (P<0.0001, one-way
ANOVA test when either internal standard was used). B. Immunohistochemical staining of
normal mammary glands and adenocarcinomas from a Foxp3sf/+Otcspf/+ mouse using rabbit
anti-FOXP3 polyclonal antibody and normal rabbit IgG as the control. C. Specific silencing
of the WT allele in breast cancer cells. Foxp3 transcripts were amplified from micro-
dissected breast cancers or normal breast epithelium by two rounds of anchored PCR and
were cloned into the TOPO vector and sequenced. The number of clones with sequences of
WT or mutant alleles in the breast cancer and normal epithelium is presented. A total of 20
clones were sequenced from each group. Data shown are from pooled samples that lack CD3
transcripts. n.d., not detectable.
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Foxp3 represses the expression of ErbB2. A. Over-expression of ErbB2 in mouse mammary
cancers. The left panels show immunohistochemical staining of a non-cancerous mammary
gland and an adjacent adenocarcinoma from a Foxp3sf/+Otcspf/+ mouse using anti-ErbB2
antibody. The right panel: Relative expression levels of ErbB2 in normal mammary
epithelium of WT and Foxp3sf/+Otcspf/+ mice and of cancer tissues from Foxp3sf/+Otcspf/+
mice as revealed by real-time RT-PCR of LCM samples. Data shown are means and S.D.
The expression of ErbB2 was normalized against either Hprt or CK19. Highly significant
differences were observed between cancerous and normal tissue (P<0.001, ANOVA test
when either internal standards were used). B. Transfection of Foxp3-V5 into TSA cells
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repressed expression of the ErbB2 locus. The left panel shows mRNA levels as measured by
real-time PCR. Data shown are means and S.D. of triplicates. The right panel shows the
protein levels by Western blot of the cell lysates using anti-ErbB2 antibody. The amount of
actin β was used as loading control, while the amount of transfected Foxp3-V5 was
measured by Western blot using anti-V5 antibodies. C. Binding of the Foxp3-V5 fusion
protein to the promoter region of the ErbB2 gene. Top panel is a diagram of the 5′ region of
the ErbB2 gene, including the promoter, exon 1, intron 1 and exon 3. The forkhead binding
motifs are illustrated with small green bars, while the regions surveyed by real-time PCR are
marked in red bars. The lower panel shows the amount of DNA precipitated by either
control IgG or anti-V5 mAb expressed as % of the total input genomic DNA. D. Foxp3-
mediated repression of the ErbB2 promotor requires forkhead binding motifs as evaluated
by dual-luciferaseR reporter assay. The promoter regions differed in the number of forkhead
binding motifs, as illustrated in the diagram on the left. Three different cell lines were
transfected with either vector control or Foxp3 (1 μg/well) in conjunction with the luciferase
reporter driven by different 5′ promoter regions of the ErbB2 gene (0.6 μg/well). pRL-TK
was used as internal control.The luciferase activity from the cells transfected with the pGL2-
basic vector was arbitrarily defined as 1.0. Data shown are means and S.D. of triplicates and
have been repeated at least three times. E. Site-directed mutagenesis of one of two
conserved regions with multiple forkhead binding motifs in the ErbB2/HER-2 promoter
prevented repression of the ErbB2 promoter by Foxp3. The two binding sites, as illustrated
in supplemental Fig. S2, were deleted individually (deleted DNA sequence, Mut A:
AAATCTGGGATCATTTA; Mut B: TTTGAATTTCAGATAAA). Right panel shows that
mutations of either site prevented FOXP3-mediated suppression. The promoter activity was
measured and normalized as detailed in D, except that the amount of promoter DNA was 0.4
μg/sample. The promoter activities of the vector groups were artificially defined as 1.0. F.
Foxp3-mediated binding to specific cis-elements in the ErbB2 promoter. Nuclear extracts
from the Foxp3-V5- (F-NE) or vector-transfected control (C-NE) TSA cells were pre-
incubated with 32P-labeled WT (*W) or mutant probes (*M) in the presence of an unlabeled
WT (W) or mutant probe (M). The mixtures were analyzed by PAGE. NS, nonspecific; FP,
free probe. The specific Foxp3-shifted band is marked by an arrow. Data shown have been
repeated three times. G. Mutation of forkhead binding motifs (Mut C) abrogated FOXP3-
mediated repression, but not basal promoter activity. As in E, except that WT, Mut B and
Mut C (mutations that inactivate the Foxp3 binding as detailed in F) of the ErbB2 promoters
were used. This experiment has been repeated twice with similar results. The differences
were compared by student t-tests with P value provided.
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Characterization of FOXP3 transcripts in primary, immortalized and malignant mammary
epithelial cells. Relative levels and isoforms of FOXP3 (the upper panel) and HER-2 (the
lower panel) mRNA. After normalizing against endogenous GAPDH, the amounts of
transcripts were compared to those found in HMEC-1, which was arbitrally defined as 1.0.
The reported ER status and the isoforms of the FOXP3 transcripts detected are indicated. To
characterize the isoforms, FOXP3 mRNA was amplified by two rounds of anchored PCR
using primers annealing to exons 1 and 12. The bulk PCR products were sequenced only if
one species was found in agarose electrophoresis. When more than one species was
observed, the PCR products were cloned and multiple clones were sequenced until all of the
species observed in the agarose gel were identified.
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FOXP3 defects in human breast cancer. A. Down-regulation of the FOXP3 protein among
human breast cancer cells. Photographs in the top panels show anti-FOXP3 staining of
normal and carcinoma tissues from the same patient, with specificity control shown at the
bottom. The number and percentage of FOXP3 positive tissues are shown in the lower
panel. Samples with nuclear staining by the anti-Foxp3 antibody were scored as positive. B.
Deletion of the FOXP3 locus in breast cancer cells. Breast cancer tissue microarray samples
were analyzed by FISH using 3 BAC clone probes surrounding a 10MB region in Xp11.2. A
typical FISH for the CEPX (green) and FOXP3 (orange) probes is shown on the left, while
the genomic structure of the X-chromosome and probe positions are illustrated in the middle
Zuo et al. Page 17













panel. A total of 238 samples were analyzed for all probes, with 223 samples providing
definitive FISH data. 28/223 samples showed deletions as detected by at least one of the 3
probes. The positions of the deletions in the 28 samples are summarized in the right panel.
C. Somatic mutation of the FOXP3 gene in breast cancer samples: summary of sequencing
data from 65 cases, including 50 formalin-fixed samples and 15 frozen samples. Genomic
DNA was isolated from matched normal and cancerous tissues from the same patients and
amplified with primers for individual exons and intron-exon boundary regions. Somatic
mutations were identified by comparing sequences from normal and cancerous samples from
the same patients. The data are from either bulk sequencing of PCR products or from the
sequencing of 5–10 clones from PCR products. Only those mutations that were observed in
multiple clones were scored. Mutations identified from 50 cases of formalin fixed samples
are marked in black, while those identified from 15 cases of frozen tissue samples are
marked in red. D. FOXP3 mutations reduced its repressor activity for the HER-2 promoter in
the SKBr-3 cell line. The left panel shows expression of mutant cDNA. The middle panel
shows luciferase activity, while the right panel shows the levels of HER-2 transcripts. The
difference between WT and 318 P> L and that between WT and 204C>R205E>K are highly
significant (P<0.01). Data shown are representative of at least 2–3 independent experiments.
E. A breast cancer sample with a somatic mutation in intron 6 (case 23) had an inactivated
FOXP3 locus. Normal mammary epithelial (N) and tumor (T) cells were isolated by LCM.
The FOXP3 transcripts were determined either by PCR using primers spanning exons 5–8 to
detect alternatively spliced products or by real-time PCR using primers spanning exons 10–
12. The upper and middle panels show photographs of PCR products of FOXP3 or GAPDH
loci, while the right panel shows the relative level of FOXP3 transcripts as determined by
real time PCR. Neither assay detected any FOXP3 transcripts in the tumor of case No. 23.
Substantial amounts of FOXP3 transcripts were detected in normal samples and tumors in
case 22 (with a synonymous mutation in exon 7), which was artificially defined as 1.0.
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FOXP3 is an important HER-2 repressor. A. Silencing of FOXP3 resulted in the up-
regulation of HER-2 in primary human mammary epithelial cells (HMEC). Early passage of
HMEC were transduced with lentiviral vector for either control sequence or FOXP3 siRNA.
The untransfected cells were removed by selection with blasticidin. At one week after
transduction, the levels of the FOXP3 and HER-2 transcripts were quantitated by real-time
PCR. Data shown are mean and SEM of relative levels of transcripts (with that in the vector-
transduced cells defined as 1.0) and represent those of three independent experiments. B.
Flow cytometry data showing the effect of FOXP3 silencing on HMEC surface HER-2
levels. HER-2-negative MDA-MB468, HER-2lo MCF-7 and HER-2hi SKBr3 cell lines were
included for comparison. C. In the Tet-off inducible FOXP3-expressing BT474, FOXP3
repressed HER-2. BT474 cells were first transfected with pTet-Off vector. The transfectants
were selected by both blasticidin and G418 in doxycycline-containing medium. The drug-
resistant cells were cultured in the absence of doxycycline for 5 days to induce FOXP3. The
cells were stained for FOXP3 and HER-2 proteins by flow cytometry. Data shown are
histograms depicting HER-2 levels among the gated FOXP3hi and FOXP3− cells based on
reactivity to the anti-Foxp3 antibody and are representative of those from two independent
experiments. D. Inverse correlation between FOXP3 expression (the top panel) and that of
the HER-2 (middle panel) among the human breast cancer samples. Tissue microassay
samples were stained with either anti-FOXP3 antibodies or anti-HER-2 antibodies and were
scored by two different pathologists in a double blind fashion. FOXP3 staining was scored
by nuclear staining with affinity-purified anti-FOXP3 antibodies. A summary of 517
FOXP3+ and 145 FOXP3− samples is shown in the bottom panel. E. Inverse correlations
between FOXP3 expression and HER-2 scores in cells with or without HER-2 amplification.
The HER-2 gene copy number was determined by FISH, while nuclear expression of
FOXP3 was determined by immunohistochemistry. Data shown are mean and S.D. of
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HER-2 scores of 425 cases of breast cancers grouped by HER-2 copy number. P values were
generated by the Mann-Whitney test.
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Foxp3 inhibits the growth and tumorigenicity of multiple breast cancer cell lines. A. Breast
cancer cell lines MCF-7, SKBr3 and TSA were transfected with equal concentrations of
either vector alone (Vector), Foxp3 or Otc cDNA. After 3 weeks of G-418 selection, the
drug resistant clones were visualized by crystal violet dye. B. Summary of the colony
numbers in three independent experiments as described in A. Data shown are means and
S.D. C. Somatic mutations identified from breast cancer samples attenuated the growth
suppression of the FOXP3. As in A & B, except that two somatic mutants were compared
with WT FOXP3 cDNA using the two human breast cancer cell lines. Expression of WT
and mutant proteins at 1 week after transfection is presented in the insert. D&E. Ectopic
expression of the ErbB2 but not the c-Myc cDNA abrogated Foxp3-mediated repression.
TSA cells were transfected with either pcDNA6-blasticidin vector or ErbB2 cDNA and
selected with blasticidin for two weeks. Pools of blasticidin-resistant cells were super-
transfected with the pEF1-G418 vector or Foxp3 cDNA. The cells were then plated and
selected with blasticidin and G418 for three weeks. The viable colonies were visualized after
staining with the crystal violet dye. D. Photographs of a representative plate showing
abrogation of Foxp3-mediated suppression by ErbB2. E. The mean and S.D. of the colony
numbers. This experiment has been repeated twice with essentially identical results. F.
Expression of Foxp3 reduced growth rate of tumors. Syngeneic BALB/c mice were injected
with 5x105/mouse Foxp3 or vector-transfected TSA cells in the flank and the sizes of the
local tumor mass were measured using a caliper. Data shown are means and S.D. and have
been repeated once. G. The survival of tumor-bearing mice was monitored over a 7-weeks
period (P=0.0015, log-rank test). As in F, except that 106 tumor cells /mouse were injected
and the mice were euthanized when they became moribund.
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